Nexalin Technology, Inc. announced the publication of a research article titled, " Evidence of a large current of transcranial alternating current stimulation directly to deep brain regions," in Nature's Molecular Psychiatry, a leading peer-reviewed journal. The study revealed for the first time, that the company?s non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, areas of the brain frequently associated with trauma and mental health disease. The study also demonstrated that the company?s non-invasive Deep Intracranial Frequency Stimulation (DIFS?) has the potential to treat neuropsychiatric disorders associated with the hippocampus, insula, amygdala, and other deep nuclei.

This achievement not only moves non-invasive neural stimulation technology from qualitative treatment to quantitative treatment, but also lays a new theoretical foundation for future neural stimulation protocols for the treatment of brain diseases.